Skip to main content
. 2018 Jan 8;9(7):7541–7556. doi: 10.18632/oncotarget.24045

Figure 6. Therapeutic efficacy of PENAO, temsirolimus and combination in the HSJD-DIPG007 orthotopic animal model.

Figure 6

(A) Survival curve of orthotopicaly-injected DIPG animals treated with vehicle, PENAO administered by alzet Pump (3 mg/kg/day 7 days/week, 4 weeks), temsirolimus (10 mg/kg/day 5 days/week 2 weeks and 5 mg/kg/day 5 days/week 2 weeks) and combination. Each treatment cohort consisted of 12 animals and tumour engraftment was assessed by neurological symptoms and/or weight loss. At endpoint animals were sacrificed and brains were examine histologically with H&E and Ki67 stains. (B) Histological analysis of harvested brains from each treatment cohort. Ki67 positive cells were quantified in 6 separate fields of view in the pons region from 3–4 animals per cohort. (C) Mass spectrometric analysis of arsenic levels in brains from vehicle and PENAO-treated DIPG xenografts. (D) Survival curve of orthotopicaly-injected DIPG animals treated with vehicle, PENAO administered intraperitonealy (10 mg/kg/day 5 days/week), temsirolimus (10 mg/kg/day 5 days/ week) and combination for 4 weeks. Each treatment cohort consisted of 12 animals and tumor engraftment was assessed by neurological symptoms and/or weight loss.